ANDAORALTABLET
Approved
Aug 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
19
Mechanism of Action
Xanthine Oxidase Inhibitors
Pharmacologic Class:
Xanthine Oxidase Inhibitor
Indications (18)
symptoms of primarysecondary gout (acute attackstophijoint destructionuric acid lithiasisand/or nephropathy)lymphomasolid tumor malignanciesurinary uric acid levels750 mg/day in female patientsdespite lifestyle changes (suchnon-dairy animal proteinoxylate rich foodsrefined sugarsincreases in oral fluidsfruitsvegetables) Limitations of Use Allopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemialeukemia
Clinical Trials (5)
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
Started Apr 2021
25 enrolled
Chronic Kidney Disease
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
Started Sep 2020
14 enrolled
Chronic Kidney Disease
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Started Jul 2019
861 enrolled
Chronic Kidney Disease
A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
Started Jan 2019
6 enrolled
Chronic Kidney Disease
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
Started Oct 2011
82 enrolled
Intercritical Gout